Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sanford-Burnham to Partner with Pfizer

Published: Tuesday, August 20, 2013
Last Updated: Tuesday, August 20, 2013
Bookmark and Share
The collaboration will see the organisations identify new therapeutic targets for preventing and treating complications of obesity and diabetes.

The team will utilize novel screening tools including systems-biology approaches and technologies developed at the Institute with the aim of discovering new therapeutic strategies for reducing insulin resistance in obesity and diabetes. 

Under the three-year agreement, multi-disciplinary teams from Sanford-Burnham and Pfizer will collaborate to identify and validate new targets for drug discovery. The collaboration combines our expertise in fundamental disease biology and muscle metabolism with Pfizer’s expertise in drug discovery. Investigators will utilize the Conrad Prebys Center for Chemical Genomics to screen for new relevant targets using investigational compounds from Pfizer as well as evaluate compounds previously identified from the NIH chemical library. Once the screening identifies compounds of interest, Sanford-Burnham and Pfizer scientists will collaborate to characterize and further study the “hit” compounds to understand their mechanism of action. These compounds will then be used as “probes” to identify novel therapeutic targets for the treatment of diabetes. 

Finding new medicines for diabetes 
“Diabetes presents an enormous public health burden. There is an acute need to translate innovative science into potential new medicines for people living with this debilitating disease,” said Tim Rolph, Vice President and Head of Cardiovascular and Metabolic Diseases Research Unit at Pfizer. “Pfizer’s collaboration with Sanford-Burnham to use their cutting-edge screen designs is an example of our strategy to work with academic innovators to discover novel therapeutics for prevention and treatment of diabetes.” Pfizer will have access to Sanford-Burnham’s team of world-class scientists and translational infrastructure dedicated to finding new approaches to targeting disease. Collaborating with researchers at a major pharmaceutical company will help us achieve our mission of translating high-impact science into new therapies. “This important collaboration focuses our tremendous scientific and translational firepower on a major medical problem – complications of obesity-related diabetes. Working with Pfizer, we can more quickly bridge the gap between basic and translational research,” said Stephen Gardell, Ph.D., senior director of scientific resources in our Diabetes and Obesity Research Center. 

Advancing drug discovery in the Prebys Center
The Prebys Center houses Sanford-Burnham’s state-of-the-art screening facility established to accelerate the rate of commercialization of basic research in an independent medical research setting. Our discovery capabilities include: ultra-high throughput screening, high-content screening, phenotypic screening, and target-deconvolution technologies. The Prebys Center is led and staffed by industry-trained professionals who work closely with Sanford-Burnham investigators and industry collaborators to translate scientific findings into actionable drug discovery projects.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

“Junk DNA” Drives Embryonic Development
An embryo is an amazing thing. From just one initial cell, an entire living, breathing body emerges, full of working cells and organs.
Thursday, December 06, 2012
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Plant Compounds Fight Together Against Colon Cancer
Research shows treating colon cancer cells with curcumin, then silymarin is more effective than treatment with each individually.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Preventing Breast Cancer with Hops
Study of hops extract suggests prevention of breast cancer through chemical pathway activation.
Treatment Advancement for Gaucher and Parkinson's Diseases
NIH scientists identify molecule that may act as a possible treatment of neurological diseases.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Liquid Biopsy Predicts Colon Cancer Recurrence
Scientists have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease’s return in some — but not all — of a small group of patients with early-stage colon cancer.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!